POSTER SESSION VI
Wednesday, March 5, 2008 — 1:00 PM - 4:00 PM
Convention Center Exhibit Hall A
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
GYNECOLOGIC PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
93
Transitional Cell Metaplasia of the Fallopian Tube Fimbria in Risk Reducing Salpingo-Oophorectomy: A Mimic of Early Tubal Carcinoma That Lacks p53 or MIB-1 Expression
(1003)
JT Rabban, BB Crawford, CB Powell, L Chen, CJ Zaloudek - UCSF, San Francisco
An Immunophenotypic Study of Fimbrial Mucosa
(914)
MC Chang, R Drapkin, FD McKeon, H Mei, EA Agoston, CP Crum - Brigham and Women's Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA
Observer Variation in the Recognition of Tubal Intraepithelial Carcinoma
(909)
JW Carlson, EA Jarboe, DW Kindelberger, CP Crum - Brigham and Women's Hospital, Boston, MA
Secretory Leukocyte Protease Inhibitor: Immunohistochemical Evidence Supporting a Fallopian Tube Origin for Serous Papillary Carcinoma
(1034)
J Sun, F Chen, WD Mojica - University at Buffalo, The State University of New York, Buffalo, NY
Ovarian Frozen Section-Final Diagnosis Correlation: Common Discrepancies and Lessons from 1054 Cases
(924)
RE Emerson - Indiana University, Indianapolis, IN
Ovarian Frozen Section Diagnosis: Use of Whole Slide Digital Imaging Shows Excellent Correlation between Virtual Slide and Original Interpretations in a Large Series of Cases
(929)
MA Fallon, DC Wilbur, ML Prasad - UMASS Memorial Medical Center, Worcester, MA; Massachusetts General Hospital, Boston, MA
Do Locations of Endosalpingiosis and Proliferative Endosalpingiosis Pose a Higher Risk of "Recurrence" after Ovarian Serous Borderline Tumors? A Clinicopathologic Study of 188 Cases
(1002)
MR Quddus, CJ Sung, MM Steinhoff, C Zhang, R Moore, WD Lawrence - Women & Infants Hospital and The Warren Alpert Medical School of Brown University, Providence, RI
Histological Grading in a Large Series of Advanced-Stage Ovarian Carcinomas by Three Widely Used Grading Systems: Prognostic Significance, Concordance Rates and Reproducibility
(962)
S Kommoss, D Schmidt, A du Bois, J Pfisterer, F Kommoss - Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany; Institute of Pathology, A2/2, Mannheim, Germany; Klinik fuer Gynaokologie und Geburtshilfe Campus Kiel, Kiel, Germany
The Non-Epithelial Lined Spaces Pattern of Invasion and the Disorganized Individual Papillae, Non-Invasive Component, of Low Grade Serous Carcinoma
(1027)
EG Silva, MT Deavers, A Malpica - The University of Texas MD Anderson Cancer Center, Houston, TX
Defining the Cut-Point between Low- and High- Grade Ovarian Serous Carcinomas with Nuclei Grade: A Clinicopathological and Molecular Genetic Analysis
(897)
A Ayhan, RJ Kurman, R Vang, S Logani, IM Shih - Johns Hopkins Medical Institutions, Baltimore, MD; Emory University School of Medicine, Atlanta, GA; Seirei Mikatahara General Hospital, Hamamatsu, Japan
Helpful Histologic Features of Serous Carcinoma during Intraoperative Diagnosis of Ovarian Tumors
(1023)
Z Schreiber, S Liang, M Pearl, E Chalas, C Tornos - Stony Brook University Medical Center, Stony Brook, NY
MicroRNA and mRNA Expression Profiling of 48 Ovarian Surface Epithelial Neoplasms
(966)
C-H Lee, S Subramanian, I Espinosa, S Zhu, KA Blood, M van de Rijn, D Huntsman, CB Gilks - Vancouver General Hospital, Vancouver, BC, Canada; Stanford University Medical Center, Stanford, CA; British Columbia Cancer Agency, Vancouver, BC, Canada
Aurora Kinase-B Expression Is Significantly Associated with Disease Recurrence in Ovarian and Primary Peritoneal Serous Papillary Cancers
(901)
A Bargaje, G Venkataraman, A Salhadar, R Hammadeh, R Potkul, S Alkan - Loyola University Medical Center, Maywood, IL
Open Tumor Rings in Clear Cell Carcinoma: Role in Differential Diagnosis with Ovarian Yolk Sac Tumor and Serous Borderline Ovarian Tumor
(898)
H Bailey, JT Rabban - UCSF, San Francisco
Ovarian Clear Cell Carcinomas Reliably Express an Immunophenotype That Is Different from High-Grade Serous Carcinoma
(910)
J Carrick, R Soslow, E Oliva, C Ewanowich, CB Gilks, M Kôbel - Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, BC, Canada; Memorial Sloan-Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA; University of Alberta, Edmonton, AB, Canada
HNF-1 Beta Expression in Ovarian Clear Cell Carcinoma
(919)
J Cuff, GE Esheba, RA Soslow, TA Longacre - Stanford University Medical Center, Stanford; Memorial Sloan-Kettering Cancer Center, NY
IMP3 Is an Extremely Poor Prognostic Marker for Ovarian Clear Cell Carcinoma
(955)
M Kôbel, H Xu, PA Bourne, BO Spoulding, D Huntsman, CB Gilks - Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, BC, Canada; University of Rochester Medical Center, Rochester, NY; Dako North America, Carpinteria, CA
The von Hippel-Lindau Gene Product (pVHL): A Diagnostic Marker for Clear Cell Carcinoma of the Ovary and Uterus
(970)
H Liu, J Shi, J Zhang, J Prichard, W Dupree, F Lin - Geisinger Medical Center, Danville, PA; Mayo Clinic, Rochester, MN
Clinicopathologic and Immunohistochemical Analysis of Mixed Epithelial Ovarian Tumors with a Clear Cell Carcinoma Component
(894)
H Asad, RA Soslow - Memorial Sloan-Kettering Cancer Center, New York, NY
button next to any title to add to Itinerary Planner...
Add
